The Coca-Cola Co K vs Smith & Nephew plc — how do they compare? The Coca-Cola Co K trades at $86.36 (market cap $372.08B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: The Coca-Cola Co K is far larger — about 29.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| KO | SNN | |
|---|---|---|
Market Cap | $372.08B | $12.54B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $38.70 |
52-Week Low | $65.67 | $28.73 |
Enterprise Value | $399.26B | $15.57B |
Dividend Yield | 2.45% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →